Table Info

Table 1.

Involvement of gut microbiota dysbiosis in CRC

Phyla and species concerned by dysbiosis in CRC	Reference
Infection with S. bovis a risk factor for colon tumors	[52]
High enrichment of Fusobacteria in colorectal carcinoma tissue	[53]
ETBF, and Fusobacterium nucletum are highly expressed in CRC tissue	[54]
Firmicutes and Fusobacteria were over-represented whereas Proteobacteria was under-represented in CRC patients; Lactococcus and Fusobacterium is more abundant while Pseudomonas and Escherichia-Shigella reduced in cancerous tissues versus adjacent tissues	[55]
Mucosa-associated E. coli of the B2 phylogroup more prevalent in CRC tissues	[56]
Fusobacterium nucleatum isolated from tumor tissue and proved to be invasive in the in vitro experiments	[57]
B. fragilis, Enterococcus Escherichia-Shigella, Klebsiella, Streptococcus, and Peptostreptococcus is abundant in CRC patients, while Roseburia- and Lachnospiraceae-related OTUs more abundant in healthy controls	[58]
CRC patients have a lower microbiota diversity and Clostridia abundance, with a high abundance of Fusobacterium and Porphyromonas at the genus level	[59]
Bifidobacterium, Faecalibacterium, and Blautia reduction, while Fusobacterium enrichment in the CRC patients; stool samples in CRC patients enriched with Paraprevotella, Eubacterium	[60]
Association of Clostridioides difficile with CRC revealed by anti-tcdB antibodies in plasma, particularly the IgA level; anti-tcdB antibodies as candidate serologic markers for CRC	[61]
Bacteroidetes cluster 1 and Firmicutes cluster 1 decreased in CRC mucosa, whereas Bacteroidetes cluster 2, Firmicutes cluster 2, pathogen cluster, and Prevotella cluster increased in CRC mucosa; compositional alterations in the microbiota differ between distal and proximal cancers	[62]

S. bovis: Streptococcus bovis; ETBF: enterotoxigenic Bacteroides fragilis; E. coli: Escherichia coli; F. nucleatum: Fusobacterium nucleatum; B. fragilis: Bacteroides fragilis; OTUs: operational taxonomic units; tcdB: clostridium difficile toxin B; IgA: immunoglobulin A

Declarations

Author contributions

SK, OZ, and ABAEG: Conceptualization, Writing—original draft. ZB, HR, AA, FBA, AM, and AC: Conceptualization, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299–309. [DOI] [PubMed] [PMC]

Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res. 2009;15:7471–8. [DOI] [PubMed]

Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. J Theor Biol. 2014;355:10–20. [DOI] [PubMed] [PMC]

Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017;14:356–65. [DOI] [PubMed]

Huang J, Jiang Z, Wang Y, Fan X, Cai J, Yao X, et al. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy. Curr Opin Pharmacol. 2020;54:1–10. [DOI] [PubMed]

Garajová I, Balsano R, Wang H, Leonardi F, Giovannetti E, Deng D, et al. The role of the microbiome in drug resistance in gastrointestinal cancers. Expert Rev Anticancer Ther. 2021;21:165–76. [DOI] [PubMed]

Shui L, Yang X, Li J, Yi C, Sun Q, Zhu H. Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy. Front Immunol. 2020;10:2989. [DOI] [PubMed] [PMC]

Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69:1510–9. [DOI] [PubMed] [PMC]

Villéger R, Lopès A, Carrier G, Veziant J, Billard E, Barnich N, et al. Intestinal microbiota: a novel target to improve anti-tumor treatment? Int J Mol Sci. 2019;20:4584. [DOI] [PubMed] [PMC]

10.

Gori S, Inno A, Belluomini L, Bocus P, Bisoffi Z, Russo A, et al. Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. Crit Rev Oncol Hematol. 2019;143:139–47. [DOI] [PubMed]

11.

Campbell SC, Wisniewski PJ 2nd. Exercise is a novel promoter of intestinal health and microbial diversity. Exerc Sport Sci Rev. 2017;45:41–7. [DOI] [PubMed]

12.

Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8:403–16. Erratum in: Cancer Discov. 2020;10:1988. [DOI] [PubMed] [PMC]

13.

Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019;178:795–806.E12. [DOI] [PubMed] [PMC]

14.

Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66:70–8. [DOI] [PubMed]

15.

Moore WEC, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol. 1974;27:961–79. [DOI] [PubMed] [PMC]

16.

Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65:330–9. [DOI] [PubMed] [PMC]

17.

Chen Z, Zhu S, Xu G. Targeting gut microbiota: a potential promising therapy for diabetic kidney disease. Am J Transl Res. 2016;8:4009–16. Erratum in: Am J Transl Res. 2018;10:333. [PubMed] [PMC]

18.

Yamashiro Y. Gut microbiota in health and disease. Ann Nutr Metab. 2017;71:242–6. [DOI] [PubMed]

19.

Ogilvie LA, Jones BV. The human gut virome: a multifaceted majority. Front Microbiol. 2015;6:918. [DOI] [PubMed] [PMC]

20.

Shkoporov AN, Hill C. Bacteriophages of the human gut: the “Known Unknown” of the microbiome. Cell Host Microbe. 2019;25:195–209. [DOI] [PubMed]

21.

Dethlefsen L, Eckburg PB, Bik EM, Relman DA. Assembly of the human intestinal microbiota. Trends Ecol Evol. 2006;21:517–23. [DOI] [PubMed]

22.

Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–14. [DOI] [PubMed] [PMC]

23.

O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688–93. [DOI] [PubMed] [PMC]

24.

Natividad JM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharmacol Res. 2013;69:42–51. [DOI] [PubMed]

25.

Upadhyaya S, Banerjee G. Type 2 diabetes and gut microbiome: at the intersection of known and unknown. Gut Microbes. 2015;6:85–92. [DOI] [PubMed] [PMC]

26.

LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013;24:160–8. [DOI] [PubMed]

27.

Chow J, Lee SM, Shen Y, Khosravi A, Mazmanian SK. Chapter 8 - host–bacterial symbiosis in health and disease. In: Fagarasan S, Cerutti A, editors. Advances in immunology. Academic Press; 2010. pp. 243–74. [DOI] [PubMed] [PMC]

28.

Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26:26191. [DOI] [PubMed] [PMC]

29.

Federico A, Dallio M, DI Sarno R, Giorgio V, Miele L. Gut microbiota, obesity and metabolic disorders. Minerva Gastroenterol Dietol. 2017;63:337–44. [DOI] [PubMed]

30.

Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590. [DOI] [PubMed] [PMC]

31.

Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, et al. Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome. Pathogens. 2019;8:126. [DOI] [PubMed] [PMC]

32.

Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, et al. Gut microbiota and cancer: from pathogenesis to therapy. Cancers (Basel). 2019;11:38. [DOI] [PubMed] [PMC]

33.

Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol. 2017;15:465–78. [DOI] [PubMed]

34.

Takeshima H, Ushijima T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. NPJ Precis Oncol. 2019;3:7. [DOI] [PubMed] [PMC]

35.

Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell. 2004;6:433–8. [DOI] [PubMed]

36.

Barnes JL, Zubair M, John K, Poirier MC, Martin FL. Carcinogens and DNA damage. Biochem Soc Trans. 2018;46:1213–24. [DOI] [PubMed] [PMC]

37.

Irigaray P, Newby JA, Clapp R, Hardell L, Howard V, Montagnier L, et al. Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed Pharmacother. 2007;61:640–58. [DOI] [PubMed]

38.

Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science. 1990;249:1007–11. [DOI] [PubMed]

39.

Comings DE. A general theory of carcinogenesis. Proc Natl Acad Sci U S A. 1973;70:3324–8. [DOI] [PubMed] [PMC]

40.

Devi PU. Basics of carcinogenesis. Health Adm. 2004;17:16–24.

41.

Chakravarthi BV, Nepal S, Varambally S. Genomic and epigenomic alterations in cancer. Am J Pathol. 2016;186:1724–35. [DOI] [PubMed] [PMC]

42.

Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120:2858–66. [DOI] [PubMed] [PMC]

43.

Chen B, Li H, Zeng X, Yang P, Liu X, Zhao X, et al. Roles of microRNA on cancer cell metabolism. J Transl Med. 2012;10:228. [DOI] [PubMed] [PMC]

44.

Khan Z, Bisen PS. Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. Biochim Biophys Acta Rev Cancer. 2013;1836:123–45. [DOI] [PubMed]

45.

Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225–39. [DOI] [PubMed]

46.

Jun JC, Rathore A, Younas H, Gilkes D, Polotsky VY. Hypoxia-inducible factors and cancer. Curr Sleep Med Rep. 2017;3:1–10. [DOI] [PubMed] [PMC]

47.

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69–84. [DOI] [PubMed]

48.

Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13:100773. [DOI] [PubMed] [PMC]

49.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. [DOI] [PubMed]

50.

Weisburger JH, Reddy BS, Narisawa T, Wynder EL. Germ-free status and colon tumor induction by N-Methyl-N’-Nitro-N-Nitrosoguanidine. Proc Soc Exp Biol Med. 1975;148:1119–21. [DOI] [PubMed]

51.

Li Y, Kundu P, Seow SW, de Matos CT, Aronsson L, Chin KC, et al. Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APC ^Min/+ mice. Carcinogenesis. 2012;33:1231–8. [DOI] [PubMed]

52.

Gupta A, Madani R, Mukhtar H. Streptococcus bovis endocarditis, a silent sign for colonic tumour. Colorectal Dis. 2010;12:164–71. [DOI] [PubMed]

53.

Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–8. [DOI] [PubMed] [PMC]

54.

Viljoen KS, Dakshinamurthy A, Goldberg P, Blackburn JM. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between Fusobacterium spp., enterotoxigenic bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS One. 2015;10:e0119462. [DOI] [PubMed] [PMC]

55.

Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol. 2015;6:20. [DOI] [PubMed] [PMC]

56.

Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One. 2013;8:e56964. [DOI] [PubMed] [PMC]

57.

Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306. [DOI] [PubMed] [PMC]

58.

Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012;6:320–9. [DOI] [PubMed] [PMC]

59.

Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105:1907–11. [DOI] [PubMed] [PMC]

60.

Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One. 2012;7:e39743. [DOI] [PubMed] [PMC]

61.

Magat EM, Balanag GA, CariÑo AM, Fellizar A, Ortin TS, Guevarra L Jr, et al. Clostridioides difficile antibody response of colorectal cancer patients versus clinically healthy individuals. Biosci Microbiota Food Health. 2020;39:123–7. [DOI] [PubMed] [PMC]

62.

Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2017;66:633–43. [DOI] [PubMed] [PMC]

63.

Handa O, Naito Y, Yoshikawa T. Helicobacter pylori: a ROS-inducing bacterial species in the stomach. Inflamm Res. 2010;59:997–1003. [DOI] [PubMed]

64.

Gagnière J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016;22:501–18. [DOI] [PubMed] [PMC]

65.

Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015;6:8727. [DOI] [PubMed] [PMC]

66.

Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res. 2014;20:859–67. [DOI] [PubMed]

67.

Kohoutova D, Smajs D, Moravkova P, Cyrany J, Moravkova M, Forstlova M, et al. Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. BMC Infect Dis. 2014;14:733. [DOI] [PubMed] [PMC]

68.

Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33:1381–90. [DOI] [PubMed]

69.

Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137:1258–68. [DOI] [PubMed]

70.

Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014;74:1311–8. [DOI] [PubMed] [PMC]

71.

Teng J, Zhao Y, Jiang Y, Wang Q, Zhang Y. Correlation between gut microbiota and lung cancer. Zhongguo Fei Ai Za Zhi. 2020;23:909–15. Chinese: [DOI] [PubMed] [PMC]

72.

Zhao Y, Liu Y, Li S, Peng Z, Liu X, Chen J, et al. Role of lung and gut microbiota on lung cancer pathogenesis. J Cancer Res Clin Oncol. 2021;147:2177–86. [DOI] [PubMed] [PMC]

73.

Fernández MF, Reina-Pérez I, Astorga JM, Rodríguez-Carrillo A, Plaza-Díaz J, Fontana L. Breast cancer and its relationship with the microbiota. Int J Environ Res Public Health. 2018;15:1747. [DOI] [PubMed] [PMC]

74.

Chen J, Douglass J, Prasath V, Neace M, Atrchian S, Manjili MH, et al. The microbiome and breast cancer: a review. Breast Cancer Res Treat. 2019;178:493–6. [DOI] [PubMed]

75.

Toumazi D, El Daccache S, Constantinou C. An unexpected link: the role of mammary and gut microbiota on breast cancer development and management (Review). Oncol Rep. 2021;45:80. [DOI] [PubMed]

76.

Samkari AA, Alsulami M, Bataweel L, Altaifi R, Altaifi A, Saleem AM, et al. Body microbiota and its relationship with benign and malignant breast tumors: a systematic review. Cureus. 2022;14:e25473. [DOI]

77.

Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10:575–82. [DOI] [PubMed]

78.

Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A. 2010;107:11537–42. [DOI] [PubMed] [PMC]

79.

Nešić D, Hsu Y, Stebbins CE. Assembly and function of a bacterial genotoxin. Nature. 2004;429:429–33. [DOI] [PubMed]

80.

Huycke MM, Moore DR. In vivo production of hydroxyl radical by Enterococcus faecalis colonizing the intestinal tract using aromatic hydroxylation. Free Radic Biol Med. 2002;33:818–26. [DOI] [PubMed]

81.

Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338:120–3. [DOI] [PubMed] [PMC]

82.

Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17:1195–214. [DOI] [PubMed]

83.

Lundberg JO, Weitzberg E, Cole JA, Benjamin N. Nitrate, bacteria and human health. Nat Rev Microbiol. 2004;2:593–602. Erratum in: Nat Rev Microbiol. 2004;2:681. [DOI] [PubMed]

84.

Maddocks OD, Scanlon KM, Donnenberg MS. An Escherichia coli effector protein promotes host mutation via depletion of DNA mismatch repair proteins. mBio. 2013;4:e00152–13. [DOI] [PubMed] [PMC]

85.

Maddocks ODK, Short AJ, Donnenberg MS, Bader S, Harrison DJ. Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans. PLoS One. 2009;4:e5517. [DOI] [PubMed] [PMC]

86.

Nejati S, Karkhah A, Darvish H, Validi M, Ebrahimpour S, Nouri HR. Influence of Helicobacter pylori virulence factors CagA and VacA on pathogenesis of gastrointestinal disorders. Microb Pathog. 2018;117:43–8. [DOI] [PubMed]

87.

Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A. 2008;105:1003–8. [DOI] [PubMed] [PMC]

88.

Yong X, Tang B, Li BS, Xie R, Hu CJ, Luo G, et al. Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways. Cell Commun Signal. 2015;13:30. [DOI] [PubMed] [PMC]

89.

Foegeding NJ, Caston RR, McClain MS, Ohi MD, Cover TL. An overview of Helicobacter pylori VacA toxin biology. Toxins (Basel). 2016;8:173. [DOI] [PubMed] [PMC]

90.

Sears CL. Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes. Clin Microbiol Rev. 2009;22:349–69. [DOI] [PubMed] [PMC]

91.

Wu S, Shin J, Zhang G, Cohen M, Franco A, Sears CL. The Bacteroides fragilis toxin binds to a specific intestinal epithelial cell receptor. Infect Immun. 2006;74:5382–90. [DOI] [PubMed] [PMC]

92.

Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599–608. [DOI] [PubMed]

93.

Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1720–8. [DOI] [PubMed]

94.

Raisch J, Rolhion N, Dubois A, Darfeuille-Michaud A, Bringer MA. Intracellular colon cancer-associated Escherichia coli promote protumoral activities of human macrophages by inducing sustained COX-2 expression. Lab Invest. 2015;95:296–307. [DOI] [PubMed]

95.

Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127:412–21. [DOI] [PubMed]

96.

Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12:661–72. [DOI] [PubMed]

97.

Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800–12. [DOI] [PubMed] [PMC]

98.

Boleij A, Tjalsma H. Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. Biol Rev Camb Philos Soc. 2012;87:701–30. [DOI] [PubMed]

99.

Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591–6. [DOI] [PubMed]

100.

Gupta S, Roy A, Dwarakanath BS. Metabolic cooperation and competition in the tumor microenvironment: implications for therapy. Front Oncol. 2017;7:68. [DOI] [PubMed] [PMC]

101.

Kovács T, Mikó E, Ujlaki G, Sári Z, Bai P. The microbiome as a component of the tumor microenvironment. Adv Exp Med Biol. 2020;1225:137–53. [DOI] [PubMed]

102.

Plottel CS, Blaser MJ. Microbiome and malignancy. Cell Host Microbe. 2011;10:324–35. [DOI] [PubMed] [PMC]

103.

Wei MQ, Ellem KA, Dunn P, West MJ, Bai CX, Vogelstein B. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer. 2007;43:490–6. [DOI] [PubMed]

104.

Baban CK, Cronin M, O’Hanlon D, O’Sullivan GC, Tangney M. Bacteria as vectors for gene therapy of cancer. Bioeng Bugs. 2010;1:385–94. [DOI] [PubMed] [PMC]

105.

Syed Khaja AS, Toor SM, El Salhat H, Faour I, Ul Haq N, Ali BR, et al. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget. 2017;8:33159–71. [DOI] [PubMed] [PMC]

106.

Vojinovic D, Radjabzadeh D, Kurilshikov A, Amin N, Wijmenga C, Franke L, et al. Relationship between gut microbiota and circulating metabolites in population-based cohorts. Nat Commun. 2019;10:5813. [DOI] [PubMed] [PMC]

107.

Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579:567–74. [DOI] [PubMed] [PMC]

108.

Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, et al. Bile acid metabolites control TH17 and Treg cell differentiation. Nature. 2019;576:143–8. Erratum in: Nature. 2020;579:E7. [DOI] [PubMed] [PMC]

109.

Fluckiger A, Daillère R, Sassi M, Sixt BS, Liu P, Loos F, et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science. 2020;369:936–42. [DOI] [PubMed]

110.

Mager LF, Burkhard R, Pett N, Cooke NCA, Brown K, Ramay H, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 2020;369:1481–9. [DOI] [PubMed]

111.

Gao R, Kong C, Huang L, Li H, Qu X, Liu Z, et al. Mucosa-associated microbiota signature in colorectal cancer. Eur J Clin Microbiol Infect Dis. 2017;36:2073–83. [DOI] [PubMed]

112.

Koi M, Okita Y, Carethers JM. Fusobacterium nucleatum infection in colorectal cancer: linking lnflammation, DNA mismatch repair and genetic and epigenetic alterations. J Anus Rectum Colon. 2018;2:37–46. [DOI] [PubMed] [PMC]

113.

Lee DW, Han SW, Kang JK, Bae JM, Kim HP, Won JK, et al. Association between Fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer. Ann Surg Oncol. 2018;25:3389–95. [DOI] [PubMed]

114.

Yu M, Kim JK, Kim SY, Cho SH, Kim MJ, Seomun G. Development and effects of simulation program for fall management. J Korean Acad Nurs Adm. 2017;23:548–57. [DOI]

115.

Zhou Z, Chen J, Yao H, Hu H. Fusobacterium and colorectal cancer. Front Oncol. 2018;8:371. [DOI] [PubMed] [PMC]

116.

Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21. Gastroenterology. 2017;152:851–66.E24. [DOI] [PubMed] [PMC]

117.

Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein claudin-1 transcription. Dig Dis Sci. 2012;57:3126–35. [DOI] [PubMed]

118.

Lam KC, Vyshenska D, Hu J, Rodrigues RR, Nilsen A, Zielke RA, et al. Transkingdom network reveals bacterial players associated with cervical cancer gene expression program. PeerJ. 2018;6:e5590. [DOI] [PubMed] [PMC]

119.

Liu Y, Lin Z, Lin Y, Chen Y, Peng XE, He F, et al. Streptococcus and prevotella are associated with the prognosis of oesophageal squamous cell carcinoma. J Med Microbiol. 2018;67:1058–68. [DOI] [PubMed]

120.

Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, et al. The human tumor microbiome is composed of tumor type–specific intracellular bacteria. Science. 2020;368:973–80. [DOI] [PubMed] [PMC]

121.

Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell. 2021;39:708–24.E11. [DOI] [PubMed]

122.

Łaniewski P, Ilhan ZE, Herbst-Kralovetz MM. The microbiome and gynaecological cancer development, prevention and therapy. Nat Rev Urol. 2020;17:232–50. [DOI] [PubMed] [PMC]

123.

Del Castillo E, Meier R, Chung M, Koestler DC, Chen T, Paster BJ, et al. The microbiomes of pancreatic and duodenum tissue overlap and are highly subject specific but differ between pancreatic cancer and noncancer subjects. Cancer Epidemiol Biomarkers Prev. 2019;28:370–83. [DOI] [PubMed] [PMC]

124.

Bekliz M, Colson P, La Scola B. The expanding family of virophages. Viruses. 2016;8:317. [DOI] [PubMed] [PMC]

125.

Yinda CK, Vanhulle E, Conceição-Neto N, Beller L, Deboutte W, Shi C, et al. Gut virome analysis of cameroonians reveals high diversity of enteric viruses, including potential interspecies transmitted viruses. mSphere. 2019;4:e00585–18. [DOI] [PubMed] [PMC]

126.

Muresu N, Sotgiu G, Saderi L, Sechi I, Cossu A, Marras V, et al. Distribution of HPV genotypes in patients with a diagnosis of anal cancer in an Italian region. Int J Environ Res Public Health. 2020;17:4516. [DOI] [PubMed] [PMC]

127.

Cantalupo PG, Katz JP, Pipas JM. Viral sequences in human cancer. Virology. 2018;513:208–16. [DOI] [PubMed] [PMC]

128.

Mollerup S, Asplund M, Friis-Nielsen J, Kjartansdóttir KR, Fridholm H, Hansen TA, et al. High-throughput sequencing-based investigation of viruses in human cancers by multienrichment approach. J Infect Dis. 2019;220:1312–24. [DOI] [PubMed] [PMC]

129.

Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;15:266–82. [DOI] [PubMed] [PMC]

130.

Zhang LL, Wei JY, Wang L, Huang SL, Chen JL. Human T-cell lymphotropic virus type 1 and its oncogenesis. Acta Pharmacol Sin. 2017;38:1093–103. [DOI] [PubMed] [PMC]

131.

Marônek M, Link R, Monteleone G, Gardlík R, Stolfi C. Viruses in cancers of the digestive system: active contributors or idle bystanders? Int J Mol Sci. 2020;21:8133. [DOI] [PubMed] [PMC]

132.

de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17–27. [DOI] [PubMed]

133.

Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25:2–23. [DOI] [PubMed] [PMC]

134.

Buitrago-Pérez A, Garaulet G, Vázquez-Carballo A, Paramio JM, García-Escudero R. Molecular signature of HPV-induced carcinogenesis: pRb, p53 and gene expression profiling. Curr Genomics. 2009;10:26–34. [DOI] [PubMed] [PMC]

135.

Emlet C, Ruffin M, Lamendella R. Enteric virome and carcinogenesis in the gut. Dig Dis Sci. 2020;65:852–64. [DOI] [PubMed]

136.

Chen W, Li F, Mead L, White H, Walker J, Ingram DA, et al. Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology. 2007;367:168–74. [DOI] [PubMed] [PMC]

137.

Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, Jansen-Dürr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A. 1999;96:1291–6. [DOI] [PubMed] [PMC]

138.

Spangle JM, Munger K. The HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PLoS Pathog. 2013;9:e1003237. [DOI] [PubMed] [PMC]

139.

Chen HP, Jiang JK, Chan CH, Teo WH, Yang CY, Chen YC, et al. Genetic polymorphisms of the human cytomegalovirus UL144 gene in colorectal cancer and its association with clinical outcome. J Gen Virol. 2015;96:3613–23. [DOI] [PubMed]

140.

Fiorina L, Ricotti M, Vanoli A, Luinetti O, Dallera E, Riboni R, et al. Systematic analysis of human oncogenic viruses in colon cancer revealed EBV latency in lymphoid infiltrates. Infect Agent Cancer. 2014;9:18. [DOI] [PubMed] [PMC]

141.

Song LB, Zhang X, Zhang CQ, Zhang Y, Pan ZZ, Liao WT, et al. Infection of Epstein-Barr virus in colorectal cancer in Chinese. Ai Zheng. 2006;25:1356–60. [PubMed]

142.

Awerkiew S, Bollschweiler E, Metzger R, Schneider PM, Hölscher AH, Pfister H. Esophageal cancer in Germany is associated with Epstein-Barr-virus but not with papillomaviruses. Med Microbiol Immunol. 2003;192:137–40. [DOI] [PubMed]

143.

Nakatsu G, Zhou H, Wu WKK, Wong SH, Coker OO, Dai Z, et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology. 2018;155:529–41.E5. [DOI] [PubMed]

144.

Johnson CH, Dejea CM, Edler D, Hoang LT, Santidrian AF, Felding BH, et al. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 2015;21:891–7. [DOI] [PubMed] [PMC]

145.

Gao R, Zhu Y, Kong C, Xia K, Li H, Zhu Y, et al. Alterations, interactions, and diagnostic potential of gut bacteria and viruses in colorectal cancer. Front Cell Infect Microbiol. 2021;11:657867. [DOI] [PubMed] [PMC]

146.

Massimino L, Lovisa S, Antonio Lamparelli L, Danese S, Ungaro F. Gut eukaryotic virome in colorectal carcinogenesis: is that a trigger? Comput Struct Biotechnol J. 2020;19:16–28. [DOI] [PubMed] [PMC]

147.

Marongiu L, Landry JJM, Rausch T, Abba ML, Delecluse S, Delecluse HJ, et al. Metagenomic analysis of primary colorectal carcinomas and their metastases identifies potential microbial risk factors. Mol Oncol. 2021;15:3363–84. [DOI] [PubMed] [PMC]

148.

Ackerman AL, Underhill DM. The mycobiome of the human urinary tract: potential roles for fungi in urology. Ann Transl Med. 2017;5:31. [DOI] [PubMed] [PMC]

149.

Delecluse S, Tsai MH, Shumilov A, Bencun M, Arrow S, Beshirova A, et al. Epstein-Barr virus induces expression of the LPAM-1 Integrin in B cells in vitro and in vivo. J Virol. 2019;93:e01618–18. [DOI] [PubMed] [PMC]

150.

Ma W, Mao Q, Xia W, Dong G, Yu C, Jiang F. Gut microbiota shapes the efficiency of cancer therapy. Front Microbiol. 2019;10:1050. [DOI] [PubMed] [PMC]

151.

Samet A, Sledzińska A, Krawczyk B, Hellmann A, Nowicki S, Kur J, et al. Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream. Eur J Clin Microbiol Infect Dis. 2013;32:1393–400. [DOI] [PubMed] [PMC]

152.

Wolochow H, Hildebrand GJ, Lamanna C. Translocation of microorganisms across the intestinal wall of the rat: effect of microbial size and concentration. J Infect Dis. 1966;116:523–8. [DOI] [PubMed]

153.

Perez-Chanona E, Trinchieri G. The role of microbiota in cancer therapy. Curr Opin Immunol. 2016;39:75–81. [DOI] [PubMed] [PMC]

154.

Erdman SE, Poutahidis T. Gut microbiota modulate host immune cells in cancer development and growth. Free Radic Biol Med. 2017;105:28–34. [DOI] [PubMed] [PMC]

155.

Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–6. [DOI] [PubMed] [PMC]

156.

Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity. 2016;45:931–43. [DOI] [PubMed]

157.

Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. [DOI] [PubMed]

158.

Scott TA, Quintaneiro LM, Norvaisas P, Lui PP, Wilson MP, Leung KY, et al. Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans. Cell. 2017;169:442–56.E18. [DOI] [PubMed] [PMC]

159.

Kim DH. Gut microbiota-mediated drug-antibiotic interactions. Drug Metab Dispos. 2015;43:1581–9. [DOI] [PubMed]

160.

Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:967–70. [DOI] [PubMed] [PMC]

161.

Klaassen CD, Cui JY. Review: mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids. Drug Metab Dispos. 2015;43:1505–21. [DOI] [PubMed] [PMC]

162.

García-González AP, Ritter AD, Shrestha S, Andersen EC, Yilmaz LS, Walhout AJM. Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics. Cell. 2017;169:431–41.E8. [DOI] [PubMed] [PMC]

163.

Guthrie L, Gupta S, Daily J, Kelly L. Human microbiome signatures of differential colorectal cancer drug metabolism. NPJ Biofilms Microbiomes. 2017;3:27. [DOI] [PubMed] [PMC]

164.

Fijlstra M, Ferdous M, Koning AM, Rings EH, Harmsen HJ, Tissing WJ. Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model. Support Care Cancer. 2015;23:1513–22. [DOI] [PubMed]

165.

Montassier E, Gastinne T, Vangay P, Al-Ghalith GA, Bruley des Varannes S, Massart S, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015;42:515–28. [DOI] [PubMed]

166.

Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, et al. The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol. 2011;93:294–300. [DOI] [PubMed]

167.

Zhang Y, Rajput A, Jin N, Wang J. Mechanisms of immunosuppression in colorectal cancer. Cancers (Basel). 2020;12:3850. [DOI] [PubMed] [PMC]

168.

Lu Y, Yuan X, Wang M, He Z, Li H, Wang J, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol. 2022;15:47. [DOI] [PubMed] [PMC]

169.

Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm. 2011;26:1–64. [DOI] [PubMed]

170.

Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27:S87–97. [DOI] [PubMed] [PMC]

171.

Rausch MP, Hastings KT. Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application. In: Ward WH, Farma JM, editors. Cutaneous melanoma: etiology and therapy. Exon Publications; 2017. pp. 121–42. [DOI] [PubMed]

172.

Harrington KJ, Andtbacka RH, Collichio F, Downey G, Chen L, Szabo Z, et al. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the phase III OPTiM trial. Onco Targets Ther. 2016;9:7081–93. [DOI] [PubMed] [PMC]

173.

Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:916–25. [DOI] [PubMed]

174.

Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, et al. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. 2020;8:e000779. [DOI] [PubMed] [PMC]

175.

Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16:121–6. [DOI] [PubMed] [PMC]

176.

Corbaux P, Maillet D, Boespflug A, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, et al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. Eur J Cancer. 2019;121:192–201. [DOI] [PubMed]

177.

Kabat AM, Srinivasan N, Maloy KJ. Modulation of immune development and function by intestinal microbiota. Trends Immunol. 2014;35:507–17. [DOI] [PubMed] [PMC]

178.

Qiu Q, Lin Y, Ma Y, Li X, Liang J, Chen Z, et al. Exploring the emerging role of the gut microbiota and tumor microenvironment in cancer immunotherapy. Front Immunol. 2021;11:612202. [DOI] [PubMed] [PMC]

179.

Matson V, Chervin CS, Gajewski TF. Cancer and the microbiome-influence of the commensal microbiota on cancer, immune responses, and immunotherapy. Gastroenterology. 2021;160:600–13. [DOI] [PubMed] [PMC]

180.

Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther. 2014;7:203–9. [DOI] [PubMed] [PMC]

181.

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2019;30:2012. Erratum in: Ann Oncol. 2017;28:1368–79. [DOI] [PubMed]

182.

Pitt JM, Vétizou M, Gomperts Boneca I, Lepage P, Chamaillard M, Zitvogel L. Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. Oncoimmunology. 2016;6:e1132137. [DOI] [PubMed] [PMC]

183.

Kim E, Ahn H, Park H. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer. Mamm Genome. 2021;32:223–31. [DOI] [PubMed] [PMC]

184.

Miller PL, Carson TL. Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review. Gut Pathog. 2020;12:43. [DOI] [PubMed] [PMC]

185.

Bianco A, Perrotta F, Barra G, Malapelle U, Rocco D, De Palma R. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. Int J Mol Sci. 2019;20:4931. [DOI] [PubMed] [PMC]

186.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7. [DOI] [PubMed]

187.

Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes. 2019;10:424–8. [DOI] [PubMed] [PMC]

188.

Shaikh FY, Gills JJ, Sears CL. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma. EBioMedicine. 2019;48:642–7. [DOI] [PubMed] [PMC]

189.

Chen H, Cong X, Wu C, Wu X, Wang J, Mao K, et al. Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9⁺ T cells. Sci Adv. 2020;6:eaax4690. [DOI] [PubMed] [PMC]

190.

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 iImmunotherapy. Cell. 2017;170:1109–19.E10. Erratum in: Cell. 2018;174:1031–2. [DOI] [PubMed] [PMC]

191.

Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr Opin Immunol. 2021;69:47–55. [DOI] [PubMed]

192.

Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome. 2018;6:92. [DOI] [PubMed] [PMC]

193.

Nagano T, Otoshi T, Hazama D, Kiriu T, Umezawa K, Katsurada N, et al. Novel cancer therapy targeting microbiome. Onco Targets Ther. 2019;12:3619–24. [DOI] [PubMed] [PMC]

194.

Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol. 2018;15:222–34. [DOI] [PubMed]

195.

Lawrie TA, Green JT, Beresford M, Wedlake L, Burden S, Davidson SE, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev. 2018;1:CD012529. [DOI] [PubMed] [PMC]

196.

Bajic JE, Johnston IN, Howarth GS, Hutchinson MR. From the bottom-up: chemotherapy and gut-brain axis dysregulation. Front Behav Neurosci. 2018;12:104. [DOI] [PubMed] [PMC]

197.

Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359:1366–70. [DOI] [PubMed]

198.

Redman MG, Ward EJ, Phillips RS. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. 2014;25:1919–29. [DOI] [PubMed]

199.

Mego M, Holec V, Drgona L, Hainova K, Ciernikova S, Zajac V. Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy. Complement Ther Med. 2013;21:712–23. [DOI] [PubMed]

200.

Gianotti L, Morelli L, Galbiati F, Rocchetti S, Coppola S, Beneduce A, et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 2010;16:167–75. [DOI] [PubMed] [PMC]

201.

Jiang C, Wang H, Xia C, Dong Q, Chen E, Qiu Y, et al. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. Cancer. 2019;125:1081–90. [DOI] [PubMed]

202.

Schroeder BO, Birchenough GMH, Ståhlman M, Arike L, Johansson MEV, Hansson GC, et al. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host Microbe. 2018;23:27–40.E7. [DOI] [PubMed] [PMC]

203.

Wang LS, Mo YY, Huang YW, Echeveste CE, Wang HT, Chen J, et al. Effects of dietary interventions on gut microbiota in humans and the possible impacts of foods on patients’ responses to cancer immunotherapy. eFood. 2020;1:279–87. [DOI] [PubMed] [PMC]

204.

Brodmann T, Endo A, Gueimonde M, Vinderola G, Kneifel W, de Vos WM, et al. Safety of novel microbes for human consumption: practical examples of assessment in the European Union. Front Microbiol. 2017;8:1725. [DOI] [PubMed] [PMC]

205.

Grigorescu I, Dumitrascu DL. Implication of gut microbiota in diabetes mellitus and obesity. Acta Endocrinol (Buchar). 2016;12:206–14. [DOI] [PubMed] [PMC]

206.

Napolitano M, Covasa M. Microbiota transplant in the treatment of obesity and diabetes: current and future perspectives. Front Microbiol. 2020;11:590370. [DOI] [PubMed] [PMC]

207.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103. [DOI] [PubMed] [PMC]

208.

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–8. [DOI] [PubMed] [PMC]

209.

Bao HD, Pang MD, Olaniran A, Zhang XH, Zhang H, Zhou Y, et al. Alterations in the diversity and composition of mice gut microbiota by lytic or temperate gut phage treatment. Appl Microbiol Biotechnol. 2018;102:10219–30. [DOI] [PubMed]

210.

Rasmussen TS, Mentzel CMJ, Kot W, Castro-Mejía JL, Zuffa S, Swann JR, et al. Faecal virome transplantation decreases symptoms of type 2 diabetes and obesity in a murine model. Gut. 2020;69:2122–30. [DOI] [PubMed]

211.

Draper LA, Ryan FJ, Smith MK, Jalanka J, Mattila E, Arkkila PA, et al. Long-term colonisation with donor bacteriophages following successful faecal microbial transplantation. Microbiome. 2018;6:220. [DOI] [PubMed] [PMC]

212.

Hsu BB, Gibson TE, Yeliseyev V, Liu Q, Lyon L, Bry L, et al. Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model. Cell Host Microbe. 2019;25:803–14.E5. [DOI] [PubMed] [PMC]